HIV integrase inhibitors

US8835411B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Yasutsuga Ueda · Clinton, US
• Timothy P. Connolly · Portland, US
• Barry Johnson · Castle Rock, US
• Chen Li · South Glastonbury, US
• B. Narasimhulu Naidu · Durham, US
• Manoj Patel · Berlin, US
• Kevin Peese · Haddam, US
• Margaret E. Sorenson · Swedesburg, US
• Michael A. Walker · Durham, US
• Michael S. Bowsher · Prospect, US
• Rongti Li · Wallingford, US

Key dates

• Filing date: Dec 6, 2011
• Grant date: Sep 16, 2014
• Expiry date: Dec 6, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.